FY2023 EPS Estimates for Virios Therapeutics, Inc. Lifted by Analyst (NASDAQ:VIRI)

Virios Therapeutics, Inc. (NASDAQ:VIRI) – Equities research analysts at HC Wainwright lifted their FY2023 earnings estimates for shares of Virios Therapeutics in a report released on Tuesday, November 14th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($0.29) for the year, up from their prior estimate of ($0.34). The consensus estimate for Virios Therapeutics’ current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Virios Therapeutics’ Q4 2023 earnings at ($0.07) EPS, Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.06) EPS and FY2024 earnings at ($0.21) EPS.

Virios Therapeutics (NASDAQ:VIRI) last posted its earnings results on Monday, November 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04.

Virios Therapeutics Stock Performance

Shares of NASDAQ VIRI opened at $0.73 on Thursday. The company has a market capitalization of $14.13 million, a P/E ratio of -1.34 and a beta of 2.15. Virios Therapeutics has a 52-week low of $0.22 and a 52-week high of $2.42. The company’s 50 day moving average price is $0.79 and its 200-day moving average price is $1.23.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new position in shares of Virios Therapeutics in the 2nd quarter worth approximately $46,000. State Street Corp increased its stake in shares of Virios Therapeutics by 397.1% in the 2nd quarter. State Street Corp now owns 52,828 shares of the company’s stock valued at $73,000 after acquiring an additional 42,200 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Virios Therapeutics by 144.3% in the 2nd quarter. Geode Capital Management LLC now owns 147,269 shares of the company’s stock valued at $203,000 after acquiring an additional 86,983 shares in the last quarter. Belvedere Trading LLC bought a new stake in shares of Virios Therapeutics in the 2nd quarter valued at $25,000. Finally, McCollum Christoferson Group LLC bought a new stake in shares of Virios Therapeutics in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 10.96% of the company’s stock.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.